IL161685A0 - An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof - Google Patents

An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Info

Publication number
IL161685A0
IL161685A0 IL16168502A IL16168502A IL161685A0 IL 161685 A0 IL161685 A0 IL 161685A0 IL 16168502 A IL16168502 A IL 16168502A IL 16168502 A IL16168502 A IL 16168502A IL 161685 A0 IL161685 A0 IL 161685A0
Authority
IL
Israel
Prior art keywords
necrosis factor
tumor necrosis
ligand receptor
inducing ligand
related apoptosis
Prior art date
Application number
IL16168502A
Other languages
English (en)
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of IL161685A0 publication Critical patent/IL161685A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
IL16168502A 2001-11-01 2002-11-01 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof IL161685A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34640201P 2001-11-01 2001-11-01
PCT/US2002/035333 WO2003037913A2 (en) 2001-11-01 2002-11-01 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Publications (1)

Publication Number Publication Date
IL161685A0 true IL161685A0 (en) 2004-09-27

Family

ID=23359208

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16168502A IL161685A0 (en) 2001-11-01 2002-11-01 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
IL161685A IL161685A (en) 2001-11-01 2004-04-29 Selective antibody for ligand-receptor binding that causes cell death by 4DR tumor necrosis factor and its uses
IL196082A IL196082A (en) 2001-11-01 2008-12-18 Nucleotide acid containing a nucleotide sequence that encodes a chain of selective antibody for ligand-receptor binding that affects cell death by TNF (tumor necrosis factor) 4DR and related uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL161685A IL161685A (en) 2001-11-01 2004-04-29 Selective antibody for ligand-receptor binding that causes cell death by 4DR tumor necrosis factor and its uses
IL196082A IL196082A (en) 2001-11-01 2008-12-18 Nucleotide acid containing a nucleotide sequence that encodes a chain of selective antibody for ligand-receptor binding that affects cell death by TNF (tumor necrosis factor) 4DR and related uses

Country Status (19)

Country Link
EP (2) EP1506011B1 (zh)
JP (1) JP4371814B2 (zh)
KR (1) KR101004098B1 (zh)
CN (1) CN100482276C (zh)
AU (1) AU2002350121B2 (zh)
BR (1) BRPI0213844B8 (zh)
CA (1) CA2465040C (zh)
CO (1) CO5580833A2 (zh)
ES (1) ES2357225T3 (zh)
HU (1) HUP0700077A3 (zh)
IL (3) IL161685A0 (zh)
MX (1) MXPA04004185A (zh)
NO (1) NO338458B1 (zh)
NZ (1) NZ532591A (zh)
PL (1) PL211755B1 (zh)
RO (1) RO123115B1 (zh)
RU (1) RU2313537C2 (zh)
WO (1) WO2003037913A2 (zh)
ZA (2) ZA200403116B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
EP2192130A1 (en) 2001-07-03 2010-06-02 Genentech, Inc. Human DR4 antibodies and uses thereof
US20040089839A1 (en) 2002-10-25 2004-05-13 Honeywell International, Inc. Fluorinated alkene refrigerant compositions
KR20090046973A (ko) 2002-11-27 2009-05-11 아이알엠 엘엘씨 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
EP2292794A3 (en) 2004-08-06 2011-07-06 Genentech, Inc. Death receptor (DR) antibody for pharmaceutical use and assays employing biomarkers for predicting sensitivity of cells to said antibody
ATE508205T1 (de) 2004-08-06 2011-05-15 Genentech Inc Tests und verfahren unter verwendung von biomarkern
CN100427505C (zh) 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
RU2409817C2 (ru) 2005-08-16 2011-01-20 Дженентек, Инк. Анализы и способы применения биомаркеров
EP1981912A2 (en) * 2006-01-13 2008-10-22 Irm, Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
WO2008073581A2 (en) * 2006-10-23 2008-06-19 The Uab Research Foundation Biomarkers for cancer sensitivity to an anti-cancer agent and uses thereof
WO2009020093A1 (ja) * 2007-08-09 2009-02-12 Daiichi Sankyo Company, Limited デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
BR112012010698A2 (pt) 2009-11-05 2016-11-29 Uab Research Foundation método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
SI2636736T1 (sl) 2010-10-29 2016-09-30 Daiichi Sankyo Company, Limited Novo anti-dr5 protitelesce
CA2832342C (en) 2011-04-29 2019-12-31 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
CN103833853B (zh) * 2013-12-25 2019-05-17 河南大学 新型死亡受体激动性多价抗体及其在制备抗肿瘤药物中的应用
CA2974807A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
MA43764A (fr) * 2016-04-05 2021-06-02 Baliopharm Ag Inhibiteur monovalent de l'interaction hutnfr1
WO2018138297A1 (en) 2017-01-27 2018-08-02 Kymab Limited Anti-opg antibodies
WO2020212461A1 (en) * 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032856A1 (en) * 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
AU734758B2 (en) 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
ES2368823T3 (es) * 1998-01-26 2011-11-22 Genentech, Inc. Anticuerpos del receptor 4 de muerte (dr4) y usos de los mismos.
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
WO2000067793A1 (en) * 1999-05-06 2000-11-16 Human Genome Sciences, Inc. Death domain containing receptor 4
IL146448A0 (en) * 1999-05-28 2002-07-25 Genentech Inc Dr4 antibodies and uses thereof
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Also Published As

Publication number Publication date
CO5580833A2 (es) 2005-11-30
IL196082A (en) 2011-04-28
MXPA04004185A (es) 2005-05-16
WO2003037913A2 (en) 2003-05-08
PL211755B1 (pl) 2012-06-29
RO123115B1 (ro) 2010-11-30
EP2287285A2 (en) 2011-02-23
CN1655814A (zh) 2005-08-17
BRPI0213844B1 (pt) 2018-12-26
EP1506011A2 (en) 2005-02-16
CN100482276C (zh) 2009-04-29
WO2003037913A3 (en) 2004-11-18
RU2004116475A (ru) 2005-04-20
NZ532591A (en) 2008-04-30
AU2002350121B2 (en) 2007-09-06
CA2465040A1 (en) 2003-05-08
EP1506011B1 (en) 2015-08-19
EP2287285A3 (en) 2012-05-02
IL161685A (en) 2011-03-31
BRPI0213844B8 (pt) 2021-05-25
ZA200507050B (en) 2010-03-31
KR20040070349A (ko) 2004-08-07
HUP0700077A2 (en) 2007-05-02
RU2313537C2 (ru) 2007-12-27
PL373531A1 (en) 2005-09-05
HUP0700077A3 (en) 2012-09-28
JP4371814B2 (ja) 2009-11-25
JP2005509414A (ja) 2005-04-14
CA2465040C (en) 2013-12-10
KR101004098B1 (ko) 2011-01-13
ES2357225T3 (es) 2011-04-20
NO338458B1 (no) 2016-08-15
NO20042269L (no) 2004-06-30
BR0213844A (pt) 2006-05-23
ZA200403116B (en) 2006-06-28
EP1506011A4 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
ZA200507050B (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
HUP0400951A3 (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
HUP0600602A3 (en) Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
EP2363404B8 (en) PSMA antibodies
EP1432444A4 (en) ANTI-BETA ANTIBODIES
HK1074206A1 (en) Anti-trail-r antibodies
EP1790663A4 (en) MONOCLONAL ANTIBODY (AD5-10) AGAINST THE TUMOR NEKROSIS FACTOR RELATED APOPTOSIS-INDUCING LIGAND RESPECTOR DR5, METHOD OF MANUFACTURE AND APPLICATIONS THEREOF
IL161439A0 (en) Cannabinoid receptor ligands
PL364624A1 (en) Cannabinoid receptor ligands
AU2001271714A1 (en) B7-like polynucleotides, polypeptides, and antibodies
EP1461082A4 (en) ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX)
EP1383801A4 (en) ANTIBODIES AGAINST CANCER
AU8066701A (en) Capsaicin receptor ligands
IL156955A0 (en) Binding domain-immunoglobulin fusion proteins
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
IL161409A0 (en) Methods for ligand discovery
AU2002365649A8 (en) Anti-dota antibody
GB0126378D0 (en) Antigen
EP1462456A4 (en) TUMOR ANTIGENS
MXPA02012429A (es) Intercambiador de aniones monodispersados.
EP1411357A4 (en) CANCER DIAGNOSTICS
AU2002351469A8 (en) Acrp30-like polynucleotides, polypeptides, and antibodies
EP1454914A4 (en) TUMOR ANTIGEN
EP1403283A4 (en) TUMOR ANTIGENS
AU9389301A (en) Peptide ligands for prostate specific antigen

Legal Events

Date Code Title Description
FF Patent granted